Literature DB >> 12627042

Effects of bilateral ovariectomy and postoperative hormonal replacement therapy with 17beta-estradiol or raloxifene on serum leptin levels.

Giovanni A Tommaselli1, Costantino Di Carlo, Anna Nasti, Elena Giordano, Gustavo Pisano, Massimiliano Pellicano, Giuseppe Bifulco, Carmine Nappi.   

Abstract

OBJECTIVE: To verify the effects of hypoestrogenism and replacement therapy on body mass index (BMI) and leptin in ovariectomized women.
DESIGN: We conducted a longitudinal study on 56 women undergoing abdominal bilateral ovariectomy divided into three groups: 19 untreated controls, 18 scheduled to receive 17beta-estradiol, and 19 on raloxifene starting 15 days after surgery. Height, weight, and BMI were recorded on the day of surgery, 5 and 15 days later, and then after 6 months. Leptin and estradiol concentrations were determined by radioimmunoassay on the day of surgery, days 1, 5, and 15, and 6 months after.
RESULTS: Leptin levels rose significantly on the day after surgery [median (range): 18.2 (9.8-25.0), 12.5 (9.1-20.9), and 20.5 (12.9-24.5); P< 0.01 v basal] and returned to values similar to baseline on day 5 in all groups. Six months later, controls showed significantly higher leptin levels in comparison with both treated women and basal values [median (range): 19.7 (10.4-22.8), 11.0 (7.6-16.9), and 13.5 (9.1-14.8) ng/ml; P< 0.01). Estradiol levels decreased in all groups, reaching statistical significance 5 days after surgery ( P< 0.01 v basal). A significant rise was observed 6 months after surgery in women treated with estrogens ( P< 0.01). Six months after surgery, BMI increased in untreated controls in comparison with treated women and baseline, although not significantly.
CONCLUSIONS: The absence of modifications in leptin on days 5 and 15 after ovariectomy suggests that, in humans, estrogens may not exert an important effect on leptin secretion. After 6 months, replacement therapy maintained leptin levels and BMI was unmodified, whereas untreated controls showed a significant increase in leptin and a trend toward higher BMI, suggesting that replacement therapy may prevent changes in fat distribution and in leptin levels.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12627042     DOI: 10.1097/00042192-200310020-00008

Source DB:  PubMed          Journal:  Menopause        ISSN: 1072-3714            Impact factor:   2.953


  4 in total

1.  Effects of estrogen-like plant compounds on the vaginal epithelium pituitary, adrenal glands, and uterus of rats.

Authors:  Gismar Mc Rodrigues; Bruno Db Borges; Leticia Gabriela Q Moreira; Érica Aparecida G Rossete; Suzelei de Castro Franca
Journal:  Exp Biol Med (Maywood)       Date:  2018-12-03

Review 2.  The effect of selective estrogen receptor modulators on type 2 diabetes onset in women: Basic and clinical insights.

Authors:  Beibei Xu; Dragana Lovre; Franck Mauvais-Jarvis
Journal:  J Diabetes Complications       Date:  2017-01-20       Impact factor: 2.852

3.  Insulin resistance with hormone replacement therapy: associations with markers of inflammation and adiposity.

Authors:  Brian C Cooper; Natalie Z Burger; Michael J Toth; Mary Cushman; Cynthia K Sites
Journal:  Am J Obstet Gynecol       Date:  2007-02       Impact factor: 8.661

Review 4.  Is there evidence that estrogen therapy promotes weight maintenance via effects on leptin?

Authors:  Alyse M Springer; Karen Foster-Schubert; Gregory J Morton; Ellen A Schur
Journal:  Menopause       Date:  2014-04       Impact factor: 2.953

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.